Literature DB >> 10726804

Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy.

S Prasad1, G G Kamath, R P Phillips.   

Abstract

PURPOSE: Ocular side effects of systemic 5-fluorouracil therapy include excessive lacrimation which often resolves on cessation of therapy. Permanent stenosis of lacrimal puncta and canaliculi is rare. This report highlights this uncommon complication of 5-fluorouracil therapy.
METHODS: Report of two cases and review of literature.
RESULTS: Severe stenosis of puncta and canaliculi may be associated with prolonged systemic 5-fluorouracil therapy.
CONCLUSION: It is important for both the oncologist and ophthalmologist to be aware of the potential ocular toxicity of 5-fluorouracil. Surgical management to relieve the epiphora is often challenging, and early intervention may be beneficial.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10726804     DOI: 10.1034/j.1600-0420.2000.078001110.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  13 in total

1.  Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy.

Authors:  Hiroyuki Tabuse; Hiroya Kashiwagi; Satoshi Hamauchi; Takahiro Tsushima; Akiko Todaka; Tomoya Yokota; Nozomu Machida; Kentaro Yamazaki; Akira Fukutomi; Yusuke Onozawa; Keita Mori; Narikazu Boku; Masao Ichinose; Hirofumi Yasui
Journal:  Gastric Cancer       Date:  2015-09-11       Impact factor: 7.370

2.  Clinical features and treatment outcomes of patients with tearing after chemotherapy.

Authors:  Jinhwan Park; Joohyun Kim; Sehyun Baek
Journal:  Eye (Lond)       Date:  2018-12-10       Impact factor: 3.775

3.  EIDOS: a mechanistic classification of adverse drug effects.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

4.  Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

Authors:  R B Raffa; R J Tallarida
Journal:  J Clin Pharm Ther       Date:  2010-06       Impact factor: 2.512

5.  Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug.

Authors:  Tsugihisa Sasaki; Hiroaki Miyashita; Tamon Miyanaga; Katsushi Yamamoto; Kazuhisa Sugiyama
Journal:  Jpn J Ophthalmol       Date:  2012-03-13       Impact factor: 2.447

6.  Predictive factors for ocular complications caused by anticancer drug S-1.

Authors:  Rika Yamada; Chie Sotozono; Takahiro Nakamura; Akihiro Nishida; Shinya Nakanishi; Masaki Hirabatake; Akihito Tsuji; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2016-02-03       Impact factor: 2.447

7.  Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen.

Authors:  A Karamitsos; V Kokkas; A Goulas; P Paraskevopoulos; K Gougoulias; V Karampatakis; K Boboridis
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

Review 8.  Breast cancer medications and vision: effects of treatments for early-stage disease.

Authors:  Alvin Eisner; Shiuh-Wen Luoh
Journal:  Curr Eye Res       Date:  2011-08-05       Impact factor: 2.424

9.  Adverse effects of the oral anticancer drug s-1: lacrimal passage impairment and specific features of corneal epitheliopathy.

Authors:  Ken-Ichi Sato; Shin-Ichi Nishimura
Journal:  Open Ophthalmol J       Date:  2013-12-30

10.  Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1.

Authors:  Reiko Kuriki; Tsuyoshi Hata; Kinuyo Nakayama; Yuichi Ito; Kazunari Misawa; Seiji Ito; Michiko Tatematsu; Norio Kaneda
Journal:  J Pharm Health Care Sci       Date:  2018-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.